J&J Intermediary Drug Rule Case Won't Get 2nd Look

Law360, New York (August 17, 2012, 4:48 PM EDT) -- The Texas Supreme Court on Friday said it won't revisit a June ruling in which it reversed a $3.8 million award against a Johnson & Johnson unit and ruled for the fist time that prescription drugs fall under the so-called learned intermediary doctrine.

The high court denied a motion for rehearing from plaintiff Patricia Hamilton, who claimed she suffered from a lupuslike syndrome allegedly caused by Remicade, a rheumatoid arthritis and Crohn's disease treatment made by Centocor Inc. A Centocor video that Hamilton viewed during the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.